PATENT CLAIM ANALYSIS

Application Number: 15744278
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-07
Patent Classification: ["424", "134100"]

Abstract:
Disclosed is a fusion polypeptide for inhibiting neovascularization, including a peptide specifically binding to vascular endothelial growth factor (VEGF) receptors, and a hydrophilic elastin-based polypeptide (hydrophilic EBP) linked to the peptide.

Claim (Index 16):
The composition according to  claim 14 , wherein the diseases caused by neovascularization is any one or more selected from the group comprising diabetic retinopathy, retinopathy of prematurity, macular degeneration, choroidal neovascularization, neovascular glaucoma, eye diseases caused by corneal neovascularization, corneal transplant rejection, corneal edema, corneal opacity, cancer, hemangioma, hemangiofibroma, rheumatoid arthritis, and psoriasis.

Metadata:
- Claim Count in Document: 10.0
- Percentile: 86.0
- Lexical Diversity: 1.31034
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['14917460', '14740194', '12789215', '14740158', '14442376']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6825235912226377
- 35 USC 102 Novelty (BERT): 0.5250282216908189
- Combined Prediction Score: 0.6667740542694558
- Mean Citation Score: 259.111848
- Max Citation Score: 305.7306
- Similarity Product: 203.4776867939472

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test